# Firesorb bioresorbable scaffold for de novo coronary artery disease: 1-year clinical outcomes.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12239348</article-id><article-id pub-id-type="pmid">40629329</article-id>
<article-id pub-id-type="publisher-id">4254</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04254-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Firesorb bioresorbable scaffold for de novo coronary artery disease: 1-year clinical outcomes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Changling</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Delong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Zhanqian</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ping</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Gan</surname><given-names>Lijun</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yundai</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Shaobin</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Shenghu</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Wen</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gao</surname><given-names>Runlin</given-names></name><address><email>gaorunlin@citmd.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Jianan</given-names></name><address><email>wangjianan111@zju.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="IA1"><collab>on behalf of the FUTURE III Investigators</collab></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/059cjpv64</institution-id><institution-id institution-id-type="GRID">grid.412465.0</institution-id><institution>Department of Cardiology, </institution><institution>The Second Affiliated Hospital, Zhejiang University School of Medicine, </institution></institution-wrap>Hangzhou, China </aff><aff id="Aff2"><label>2</label>State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China </aff><aff id="Aff3"><label>3</label>Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Hangzhou, 310009 China </aff><aff id="Aff4"><label>4</label>Transvascular Implantation Devices Research Institute, Binjiang District, Hang Zhou, 310053 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0590dnz19</institution-id><institution-id institution-id-type="GRID">grid.415105.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 9430 5605</institution-id><institution>Department of Cardiology, National Center for Cardiovascular Diseases, </institution><institution>Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, </institution></institution-wrap>Beijing, China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02yng3249</institution-id><institution-id institution-id-type="GRID">grid.440229.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 7789</institution-id><institution>Department of Cardiology, </institution><institution>Inner Mongolia Autonomous Region People&#x02019;s Hospital, </institution></institution-wrap>Hohhot, China </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f8z2f57</institution-id><institution-id institution-id-type="GRID">grid.452884.7</institution-id><institution>Department of Cardiology, </institution><institution>The First People&#x02019;s Hospital of Yulin, </institution></institution-wrap>Yulin, China </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05e8kbn88</institution-id><institution-id institution-id-type="GRID">grid.452252.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 8342 692X</institution-id><institution>Department of Cardiology, </institution><institution>Affiliated Hospital of Jining Medical University, </institution></institution-wrap>Jining, China </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04gw3ra78</institution-id><institution-id institution-id-type="GRID">grid.414252.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1761 8894</institution-id><institution>Department of Cardiology, </institution><institution>Chinese PLA General Hospital, </institution></institution-wrap>Beijing, China </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01ey7we33</institution-id><institution-id institution-id-type="GRID">grid.452354.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 9055</institution-id><institution>Department of Cardiology, </institution><institution>Daqing Oilfield General Hospital, </institution></institution-wrap>Daqing, China </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02h8a1848</institution-id><institution-id institution-id-type="GRID">grid.412194.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1761 9803</institution-id><institution>Department of Cardiology, </institution><institution>General Hospital of Ningxia Medical University, </institution></institution-wrap>Ningxia, China </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04gz17b59</institution-id><institution-id institution-id-type="GRID">grid.452743.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1788 4869</institution-id><institution>Department of Cardiology, </institution><institution>Northern Jiangsu People&#x02019;s Hospital, </institution></institution-wrap>Yangzhou, China </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/048q23a93</institution-id><institution-id institution-id-type="GRID">grid.452207.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 0558</institution-id><institution>Department of Cardiology, </institution><institution>Xuzhou Central Hospital, </institution></institution-wrap>Xuzhou, China </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>419</elocation-id><history><date date-type="received"><day>17</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>6</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par17">The first-generation bioresorbable scaffolds (BRS) have been associated with higher rates of device-related adverse outcomes in comparison to everolimus-eluting stents. We aimed to evaluate the efficacy and safety of the thinner-strut (100/125&#x000a0;&#x003bc;m) poly-L-lactic acid-based sirolimus-eluting Firesorb BRS in patients with de novo coronary lesions.</p></sec><sec><title>Methods</title><p id="Par18">Patient-level data derived from 1205 patients in the FUTURE-II RCT (<italic>n</italic>&#x02009;=&#x02009;215) and FUTURE-III registry (<italic>n</italic>&#x02009;=&#x02009;990) were prospectively collected, pooled, and analyzed. The primary endpoint of 1-year target lesion failure (TLF) was defined as a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. The patient-oriented composite endpoint (POCE) of all-cause death, any myocardial infarction, or any revascularization was also analyzed.</p></sec><sec><title>Results</title><p id="Par19">At 1-year follow-up, the cumulative rate of TLF was 1.67%, with an upper 95% confidence interval of 2.57%, significantly lower than the objective performance criterion goal of 6.6% (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). The rate of single TLF components was 0.42% for cardiac death, 0.92% for target vessel myocardial infarction, and 0.42% for ischemia-driven target lesion revascularization. The cumulative rate of POCE at 1&#x000a0;year was 3.34%. No patient experienced definite or probable device thrombosis during 1-year follow-up.</p></sec><sec><title>Conclusions</title><p id="Par20">This pooled, patient-level analysis indicates that the thinner strut Firesorb BRS exhibits promising 1-year efficacy and safety profiles with regard to TLF. However, our findings are only applicable to non-complex lesions; large-scale randomized clinical trials powered to assess clinical endpoints are necessary to evaluate the strategy of Firesorb BRS compared to drug-eluting stents.</p></sec><sec><title>Trial registration</title><p id="Par21">ClinicalTrials.gov Identifier: NCT02890160 and NCT03660202.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04254-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Bioresorbable scaffolds</kwd><kwd>Coronary artery diseases</kwd><kwd>Percutaneous coronary intervention</kwd><kwd>Target lesion failure</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100018537</institution-id><institution>National Science and Technology Major Project</institution></institution-wrap></funding-source><award-id>2023ZD0504100</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Transvascular Implantation Devices Research Institute</institution></funding-source><award-id>KY012024002</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82170332</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par36">Despite the simplicity and safety of latest-generation drug-eluting stent (DES) [<xref ref-type="bibr" rid="CR1">1</xref>], permanent intravascular implants elicit complications such as restenosis, stent thrombosis, neoatherosclerosis, and may partially impair vasomotor function of the target vessels [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. In this context, fully bioresorbable scaffolds (BRS) eluting anti-restenotic drugs were developed as an alternative approach to provide a short-term arterial support until the elution process is completed. In contrast to the generally encouraging outcomes from early investigational studies and clinical trials [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>], randomized trials with longer follow-up periods and meta-analyses showed inferior clinical results, especially the device thrombosis (DT) rates, in comparison to metallic DES [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Strut thickness (&#x0003e;&#x02009;150&#x000a0;&#x003bc;m), which tends to be twice that of metallic stents, might be the most compelling explanation, leading to greater strut protrusion and turbulent flow, increased neointimal growth, and unfavorable resorption-related process [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Several BRS with thinner struts have demonstrated promising efficacy in infrapopliteal artery disease and animal coronary artery models [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].
</p><p id="Par37">Firesorb BRS (MicroPort, Shanghai, China), a thinner-strut (100/125&#x000a0;&#x003bc;m) poly-L-lactic acid (PLLA)-based sirolimus-eluting BRS, is designed to reduce lumen protrusion and improve the physiological indices of local blood flow. A first-in-man study has assessed the preliminary feasibility and safety of the novel device [<xref ref-type="bibr" rid="CR14">14</xref>]. The later multicenter randomized controlled trial (RCT) demonstrated that its angiographic efficacy regarding in-segment late loss was noninferior to the cobalt-chromium everolimus-eluting stent (CoCr-EES) [<xref ref-type="bibr" rid="CR15">15</xref>]. Here, we conducted the FUTURE-III (A Trial of Firesorb in Patients With Coronary Artery Disease) study to further evaluate the safety and efficacy with a larger sample size and examine the objective performance criterion (OPC) for target lesion failure (TLF).</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and participants</title><p id="Par38">The FUTURE-III trial is conducted to evaluate the safety and efficacy of the Firesorb BRS in patients with de novo coronary lesions. The study included 215 subjects from the FUTURE-II randomized trial and 990 subjects from the FUTURE-III registry. The FUTURE-II RCT compared the Firesorb BRS and cobalt-chromium everolimus-eluting stents in patients with no more than two de novo lesions. The FUTURE-III registry is a prospective, multicenter, single-arm clinical study. Patients aged 18 to 75&#x000a0;years with chronic coronary syndrome or stabilized acute coronary syndrome were eligible for scanning. Patients were suitable for enrollment if they had: (1) one or two de novo target lesions with TIMI flow&#x02009;&#x02265;&#x02009;1 and a visual stenosis of&#x02009;&#x02265;&#x02009;70% or&#x02009;&#x02265;&#x02009;50% with objective evidence of ischemia; if two target lesions are present, they must be present in different major epicardial vessels; (2) visual diameters of the lesions limited to&#x02009;&#x02265;&#x02009;2.5 and&#x02009;&#x02264;&#x02009;4.0&#x000a0;mm, lesion length limited to&#x02009;&#x02264;&#x02009;25&#x000a0;mm. Patients were excluded if they had (1) life expectancy&#x02009;&#x0003c;&#x02009;1&#x000a0;year; (2) recent myocardial infarction (MI) (&#x0003c;&#x02009;1&#x000a0;week); (3) bleeding diathesis or known anticoagulation dysfunction; (4) heart failure with a left ventricular ejection fraction of&#x02009;&#x0003c;&#x02009;40%; (5) included in another RCT; (6) severe left main artery disease; (7) major vessel ostial lesions; (8) bifurcation lesions with a side-branch reference vessel diameter&#x02009;&#x0003e;&#x02009;2.0&#x000a0;mm; (9) severe triple vessel lesion and required revascularization; (10) in-stent restenosis lesions. A brief summary of these two trials is provided in Additional file 1: Table&#x000a0;1. The participants using Firesorb BRS were pooled and analyzed at the patient level. The study was approved by the local ethics committee and was conducted in part to meet the China Food and Drug Administration&#x02019;s (CFDA) prospective OPC study requirements for new stents. All participants provided written informed consent for the procedure and the follow-up protocol.
</p></sec><sec id="Sec4"><title>Study device</title><p id="Par39">The Firesorb BRS is a balloon-expandable highly crystallized PLLA backbone scaffold system abluminally coated with PDLLA mixed with sirolimus (4&#x000a0;&#x003bc;g/mm) using highly accurate and precise point spraying techniques. The total strut thickness of the Firesorb BRS is 100&#x000a0;&#x003bc;m for scaffolds with diameters of 2.5 and 2.75&#x000a0;mm and 125&#x000a0;&#x003bc;m for scaffolds with diameters of 3.0 to 4.0&#x000a0;mm. The device sizes applied in the present study ranged from 2.5 to 4.0&#x000a0;mm in diameter and 13 to 29&#x000a0;mm in length. All the BRS were stored at&#x02009;&#x0003c;&#x02009;25&#x02103;. Based on our in vitro experiments, the backbone is designed to be absorbed within approximately 3&#x000a0;years, with an average molecular weight loss of 93% and a mass loss of 44% at 24&#x000a0;months [<xref ref-type="bibr" rid="CR15">15</xref>]. Consistent with these findings, the first-in-man study with 3-year imaging outcomes demonstrated appropriate intima healing, extensive strut coverage, and a very low incidence of late scaffold discontinuity [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec5"><title>Study procedure</title><p id="Par40">Percutaneous coronary intervention (PCI) was performed under dual antiplatelet therapy (DAPT) with aspirin (100&#x000a0;mg/day) and clopidogrel (75&#x000a0;mg/day) or ticagrelor (90&#x000a0;mg twice a day). For patients that were not pre-treated, 300-mg loading doses of aspirin and clopidogrel or 180-mg ticagrelor were administered before the invasive procedure. Unfractionated heparin (70&#x02013;100 U/kg, intravenous) was administered before PCI and maintained to keep the activated clotting time at 250 to 350&#x000a0;s during the procedure. Optimal pre-dilation, stent sizing and post-dilation (PSP) techniques were highly recommended [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Optimal target lesion pre-dilation was pre-specified to achieve a nominal balloon diameter-to-reference vessel diameter (RVD) ratio of 1:1. The scaffold diameter should match the reference vessel diameter to ensure optimal apposition and minimize complications. Optimal deployment was defined by a BRS nominal diameter to RVD ratio between 0.85 and 1.15 [<xref ref-type="bibr" rid="CR18">18</xref>]. Optimal post-dilation was pre-specified using a non-compliant balloon at high pressure (&#x02265;&#x02009;16&#x000a0;atm), with the balloon diameter exceeding the nominal scaffold diameter but not by&#x02009;&#x0003e;&#x02009;0.50&#x000a0;mm. DAPT was prescribed for a minimum of 12&#x000a0;months, and statins were prescribed to all subjects after PCI unless contraindicated.</p></sec><sec id="Sec6"><title>Endpoints</title><p id="Par41">All subjects were planned to follow up at 1&#x000a0;month, 6&#x000a0;months, and yearly up to 5&#x000a0;years after stent implantation. The primary outcome was 1-year TLF, which was a composite endpoint containing cardiac death, target vessel myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (ID-TLR). Secondary endpoints were as described below: device success, lesion success, and clinical success; the patient-oriented composite endpoint (POCE), defined as a composite of all-cause death, any MI, or any revascularization; TLF or POCE and its individual components across the follow-up period; and definite or probable DT. Lesion success was defined as successful treatment of all target lesions using at least one study device with final in-scaffold/stent residual stenosis&#x02009;&#x0003c;&#x02009;30%. Device success was defined as successful scaffold delivery/deployment at the target lesion and delivery system withdrawal with final in-scaffold residual stenosis&#x02009;&#x0003c;&#x02009;30%. Clinical success was defined as patients with lesion success and no in-hospital (&#x02264;&#x02009;7&#x000a0;days) TLF. MI was defined as evidence of myocardial injury with necrosis according to the Fourth Universal Definition of Myocardial Infarction [<xref ref-type="bibr" rid="CR19">19</xref>]. Cardiac death was defined as any death caused by cardiac factors or either unknown or undeterminable factors. Quantitative coronary angiography (QCA) was performed by two experienced and independent observers at core lab (COREMED Medical Technology Co., Ltd, Beijing, China). For each lesion, measurements were conducted in triplicate and average values were recorded. An independent clinical events committee, which was blinded to patient identity, adjudicated all events.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par42">The overall sample size for the FUTURE-III trial was calculated based on the primary endpoint, TLF at 1&#x000a0;year. The performance goal (PG) for the primary endpoint is prespecified as 6.6% according to the 1-year outcomes meta-analysis of the Absorb BRS [<xref ref-type="bibr" rid="CR20">20</xref>], and an expected target value of 4.4% according to the TARGET II trial was chosen [<xref ref-type="bibr" rid="CR21">21</xref>]. Assuming a 5% attrition rate of follow-up, a sample size of 1200 subjects was required to provide 89% power to meet the prespecified PG at a 2-sided type 1 error rate of 5%. The primary endpoint of TLF at the patient level was analyzed in the full analysis set (FAS). Safety was assessed in all included subjects. Continuous variables are described as means standard deviations and categorical variables are reported as percentages. Time&#x02013;to&#x02013;first event curves were performed using Kaplan&#x02013;Meier estimates. Average hazard ratios were computed with Cox proportional hazard models. All statistical analyses were performed using R version 4.1.2 (R Foundation for Statistical Computing).</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Patient and procedural characteristics</title><p id="Par43">As shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, the study pooled patient-level data derived from 1,205 patients. The mean age was 58.00&#x000a0;years, the mean body mass index was 25.39, and 73.5% of patients were men. More than a quarter of the patients had diabetes (26.2%). A total of 14.1% had a history of MI, 12.8% had prior PCI, 38.3% had hyperlipidemia, 33.6% were current smokers, and 78.9% were diagnosed with unstable angina.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">FUTURE-III OPC Study<break/>(<italic>N</italic>&#x02009;=&#x02009;1205)</th><th align="left">FUTURE-II RCT<break/><italic>N</italic>&#x02009;=&#x02009;215)</th><th align="left">FUTURE-III Registry<break/>(<italic>N</italic>&#x02009;=&#x02009;990)</th></tr></thead><tbody><tr><td align="left">Male</td><td align="left">886 (73.5)</td><td align="left">155 (72.1)</td><td align="left">731 (73.8)</td></tr><tr><td align="left">Age, yrs</td><td align="left">58.00&#x02009;&#x000b1;&#x02009;9.71</td><td align="left">56.54&#x02009;&#x000b1;&#x02009;9.63</td><td align="left">58.32&#x02009;&#x000b1;&#x02009;9.70</td></tr><tr><td align="left">Body mass index, kg/m<sup>2</sup></td><td align="left">25.39&#x02009;&#x000b1;&#x02009;3.45</td><td align="left">25.36&#x02009;&#x000b1;&#x02009;3.37</td><td align="left">25.40&#x02009;&#x000b1;&#x02009;3.47</td></tr><tr><td align="left">Hypertension</td><td align="left">728 (60.4)</td><td align="left">118 (54.9)</td><td align="left">610 (61.6)</td></tr><tr><td align="left">Diabetes mellitus</td><td align="left">316 (26.2)</td><td align="left">55 (25.6)</td><td align="left">261 (26.4)</td></tr><tr><td align="left">Hyperlipidemia</td><td align="left">462 (38.3)</td><td align="left">88 (40.9)</td><td align="left">374 (37.8)</td></tr><tr><td align="left">Chronic kidney disease</td><td align="left">50 (4.1)</td><td align="left">7 (3.3)</td><td align="left">43 (4.3)</td></tr><tr><td align="left">Current smoker</td><td align="left">405 (33.6)</td><td align="left">83 (38.6)</td><td align="left">322 (32.5)</td></tr><tr><td align="left">Previous MI</td><td align="left">170 (14.1)</td><td align="left">33 (15.3)</td><td align="left">137 (13.8)</td></tr><tr><td align="left">Previous PCI</td><td align="left">154 (12.8)</td><td align="left">30 (14.0)</td><td align="left">124 (12.5)</td></tr><tr><td align="left">Previous CABG</td><td align="left">3 (0.2)</td><td align="left">0 (0)</td><td align="left">3 (0.3)</td></tr><tr><td align="left">LVEF, %</td><td align="left">62.93&#x02009;&#x000b1;&#x02009;6.66</td><td align="left">62.67&#x02009;&#x000b1;&#x02009;6.22</td><td align="left">63.01&#x02009;&#x000b1;&#x02009;9.10</td></tr><tr><td align="left" colspan="4">Clinical presentation</td></tr><tr><td align="left">&#x02003;Silent ischemia</td><td align="left">77 (6.4)</td><td align="left">20 (9.3)</td><td align="left">57 (5.8)</td></tr><tr><td align="left">&#x02003;Stable angina</td><td align="left">177 (14.7)</td><td align="left">38 (17.7)</td><td align="left">139 (14.0)</td></tr><tr><td align="left">&#x02003;Unstable angina</td><td align="left">951 (78.9)</td><td align="left">157 (73.0)</td><td align="left">794 (80.2)</td></tr><tr><td align="left">DAPT at discharge</td><td align="left">1167 (96.9)</td><td align="left">204 (94.5)</td><td align="left">963 (97.3)</td></tr><tr><td align="left">DAPT at 1-year follow-up</td><td align="left">1116 (92.6)</td><td align="left">203 (94.4)</td><td align="left">913 (92.2)</td></tr></tbody></table><table-wrap-foot><p>Values are <italic>n</italic> (%) or mean &#x000b1; SD</p><p><italic>Abbreviations</italic>
<italic>OPC</italic> objective performance criterion, <italic>RCT</italic> randomized controlled trial, <italic>MI</italic> myocardial infarction, <italic>PCI</italic> percutaneous coronary intervention, <italic>CABG</italic> coronary artery bypass graft, <italic>LVEF</italic> left ventricle ejection fraction, <italic>DAPT</italic>&#x000a0;dual antiplatelet therapy</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Angiographic outcomes</title><p id="Par44">The procedural outcomes are presented in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. A total of 1236 lesions was treated with Firesorb BRS in our study, and nearly a half of the target lesions (53.6%) were located in the left anterior descending artery. According to baseline QCA, the average RVD, lesion length, minimum lumen diameter (MLD), and percent diameter stenosis (DS) were 2.94&#x000a0;mm, 13.83&#x000a0;mm, 0.94&#x000a0;mm, and 68.21%, respectively. Overall, pre-dilation was performed in 99.9% of patients, and post-dilation was performed in 95.3% of patients. The mean implanted device diameter was 3.24&#x000a0;mm with a device length of 22.10&#x000a0;mm. After the procedure, the in-device MLD was increased to 2.64, leading to a residual in-device percent DS of 12.07%. The overall lesion success, device success, and clinical success rates were 100%, 99.9%, and 99.2%, respectively.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Procedural characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">FUTURE-III OPC Study<break/>(<italic>N</italic><sub>L</sub>&#x02009;=&#x02009;1236)</th><th align="left">FUTURE-II RCT<break/>(<italic>N</italic><sub>L</sub>&#x02009;=&#x02009;221)</th><th align="left">FUTURE-III Registry<break/>(<italic>N</italic><sub>L</sub>&#x02009;=&#x02009;1015)</th></tr></thead><tbody><tr><td align="left" colspan="4">Target vessel location</td></tr><tr><td align="left">&#x02003;Left anterior descending</td><td align="left">663 (53.6)</td><td align="left">129 (58.4)</td><td align="left">534 (52.6)</td></tr><tr><td align="left">&#x02003;Left circumflex</td><td align="left">245 (19.8)</td><td align="left">43 (19.5)</td><td align="left">202 (19.9)</td></tr><tr><td align="left">&#x02003;Right coronary artery</td><td align="left">328 (26.5)</td><td align="left">49 (22.2)</td><td align="left">279 (27.5)</td></tr><tr><td align="left" colspan="4">Number of target lesions treated</td></tr><tr><td align="left">&#x02003;1</td><td align="left">1174 (97.4)</td><td align="left">209 (97.2)</td><td align="left">965 (97.5)</td></tr><tr><td align="left">&#x02003;2</td><td align="left">31 (2.6)</td><td align="left">6 (2.8)</td><td align="left">25 (2.5)</td></tr><tr><td align="left">Pre-dilation</td><td align="left">1235 (99.9)</td><td align="left">221 (100)</td><td align="left">1014 (99.9)</td></tr><tr><td align="left">&#x02003;Maximum balloon diameter, mm</td><td align="left">2.81&#x02009;&#x000b1;&#x02009;0.50</td><td align="left">2.77&#x02009;&#x000b1;&#x02009;0.44</td><td align="left">2.82&#x02009;&#x000b1;&#x02009;0.51</td></tr><tr><td align="left">&#x02003;Balloon diameter/RVD ratio</td><td align="left">0.97&#x02009;&#x000b1;&#x02009;0.16</td><td align="left">0.97&#x02009;&#x000b1;&#x02009;0.14</td><td align="left">0.97&#x02009;&#x000b1;&#x02009;0.16</td></tr><tr><td align="left">&#x02003;Maximum pressure, atm</td><td align="left">12.65&#x02009;&#x000b1;&#x02009;2.87</td><td align="left">12.46&#x02009;&#x000b1;&#x02009;3.13</td><td align="left">12.69&#x02009;&#x000b1;&#x02009;2.81</td></tr><tr><td align="left">&#x02003;Optimal pre-dilation</td><td align="left">509 (41.2)</td><td align="left">95 (43.0)</td><td align="left">414 (40.8)</td></tr><tr><td align="left" colspan="4">Study device implantation</td></tr><tr><td align="left">&#x02003;Total device length, mm</td><td align="left">22.10&#x02009;&#x000b1;&#x02009;5.26</td><td align="left">21.13&#x02009;&#x000b1;&#x02009;5.03</td><td align="left">22.31&#x02009;&#x000b1;&#x02009;5.29</td></tr><tr><td align="left">&#x02003;Device diameter, mm</td><td align="left">3.24&#x02009;&#x000b1;&#x02009;0.47</td><td align="left">3.19&#x02009;&#x000b1;&#x02009;0.46</td><td align="left">3.25&#x02009;&#x000b1;&#x02009;0.47</td></tr><tr><td align="left">&#x02003;Device diameter/RVD</td><td align="left">1.11&#x02009;&#x000b1;&#x02009;0.11</td><td align="left">1.11&#x02009;&#x000b1;&#x02009;0.11</td><td align="left">1.11&#x02009;&#x000b1;&#x02009;0.10</td></tr><tr><td align="left">&#x02003;Maximum pressure, atm</td><td align="left">11.39&#x02009;&#x000b1;&#x02009;2.22</td><td align="left">11.86&#x02009;&#x000b1;&#x02009;2.43</td><td align="left">11.28&#x02009;&#x000b1;&#x02009;2.15</td></tr><tr><td align="left">&#x02003;Optimal deployment</td><td align="left">836 (67.6)</td><td align="left">150 (68.9)</td><td align="left">686 (67.6)</td></tr><tr><td align="left">Post-dilation</td><td align="left">1178 (95.3)</td><td align="left">211 (95.5)</td><td align="left">967 (95.3)</td></tr><tr><td align="left">&#x02003;Balloon diameter, mm</td><td align="left">3.36&#x02009;&#x000b1;&#x02009;0.48</td><td align="left">3.36&#x02009;&#x000b1;&#x02009;0.49</td><td align="left">3.36&#x02009;&#x000b1;&#x02009;0.48</td></tr><tr><td align="left">&#x02003;Balloon diameter/RVD ratio</td><td align="left">1.15&#x02009;&#x000b1;&#x02009;0.11</td><td align="left">1.17&#x02009;&#x000b1;&#x02009;0.12</td><td align="left">1.15&#x02009;&#x000b1;&#x02009;0.11</td></tr><tr><td align="left">&#x02003;Balloon diameter/RVD ratio&#x02009;&#x02265;&#x02009;1.1:1</td><td align="left">792 (64.1)</td><td align="left">153 (69.2)</td><td align="left">639 (63.0)</td></tr><tr><td align="left">&#x02003;Maximum pressure, atm</td><td align="left">16.76&#x02009;&#x000b1;&#x02009;3.03</td><td align="left">17.09&#x02009;&#x000b1;&#x02009;2.88</td><td align="left">16.67&#x02009;&#x000b1;&#x02009;3.07</td></tr><tr><td align="left">&#x02003;&#x02265;&#x02009;16 atm</td><td align="left">839 (67.9)</td><td align="left">173 (78.3)</td><td align="left">666 (65.6)</td></tr><tr><td align="left">&#x02003;Optimal post-dilation</td><td align="left">773 (62.5)</td><td align="left">162 (73.3)</td><td align="left">611 (60.2)</td></tr><tr><td align="left">Bailout stenting during procedure</td><td align="left">14 (1.1)</td><td align="left">3 (1.4)</td><td align="left">11 (1.1)</td></tr><tr><td align="left">Intracoronary imaging use</td><td align="left">189 (15.3)</td><td align="left">39 (17.6)</td><td align="left">150 (14.8)</td></tr><tr><td align="left" colspan="4">Pre-procedure QCA</td></tr><tr><td align="left">&#x02003;RVD, mm</td><td align="left">2.94&#x02009;&#x000b1;&#x02009;0.49</td><td align="left">2.90&#x02009;&#x000b1;&#x02009;0.47</td><td align="left">2.95&#x02009;&#x000b1;&#x02009;0.49</td></tr><tr><td align="left">&#x02003;Lesion length, mm</td><td align="left">13.83&#x02009;&#x000b1;&#x02009;5.24</td><td align="left">15.20&#x02009;&#x000b1;&#x02009;6.08</td><td align="left">13.53&#x02009;&#x000b1;&#x02009;4.99</td></tr><tr><td align="left">&#x02003;MLD, mm</td><td align="left">0.94&#x02009;&#x000b1;&#x02009;0.39</td><td align="left">0.89&#x02009;&#x000b1;&#x02009;0.37</td><td align="left">0.95&#x02009;&#x000b1;&#x02009;0.39</td></tr><tr><td align="left">&#x02003;DS, %</td><td align="left">68.21&#x02009;&#x000b1;&#x02009;11.75</td><td align="left">69.44&#x02009;&#x000b1;&#x02009;11.07</td><td align="left">67.94&#x02009;&#x000b1;&#x02009;11.88</td></tr><tr><td align="left" colspan="4">Post-procedure QCA</td></tr><tr><td align="left">&#x02003;MLD (in-device)</td><td align="left">2.64&#x02009;&#x000b1;&#x02009;0.45</td><td align="left">2.59&#x02009;&#x000b1;&#x02009;0.44</td><td align="left">2.65&#x02009;&#x000b1;&#x02009;0.45</td></tr><tr><td align="left">&#x02003;MLD (in-segment)</td><td align="left">2.52&#x02009;&#x000b1;&#x02009;0.45</td><td align="left">2.48&#x02009;&#x000b1;&#x02009;0.43</td><td align="left">2.53&#x02009;&#x000b1;&#x02009;0.45</td></tr><tr><td align="left">&#x02003;DS, % (in-device)</td><td align="left">12.07&#x02009;&#x000b1;&#x02009;6.55</td><td align="left">12.08&#x02009;&#x000b1;&#x02009;6.42</td><td align="left">12.08&#x02009;&#x000b1;&#x02009;6.60</td></tr><tr><td align="left">&#x02003;DS, % (in-segment)</td><td align="left">13.81&#x02009;&#x000b1;&#x02009;6.84</td><td align="left">14.15&#x02009;&#x000b1;&#x02009;6.75</td><td align="left">13.75&#x02009;&#x000b1;&#x02009;6.86</td></tr><tr><td align="left">Lesion success</td><td align="left">1236 (100)</td><td align="left">221 (100)</td><td align="left">1015 (100)</td></tr><tr><td align="left">Device success</td><td align="left">1235 (99.9)</td><td align="left">222 (99.6)</td><td align="left">1013 (99.8)</td></tr><tr><td align="left">Clinical success, patient level</td><td align="left">1195 (99.2)</td><td align="left">213 (99.1)</td><td align="left">982 (99.2)</td></tr></tbody></table><table-wrap-foot><p>Values are n (%) or mean &#x000b1; SD</p><p><italic>Abbreviations</italic>
<italic>N</italic><sub><italic>L</italic></sub> number of lesions, <italic>QCA</italic> quantitative coronary angiography, <italic>RVD</italic> reference vessel diameter, <italic>MLD</italic> minimal lumen diameter, <italic>DS</italic> diameter stenosis, other abbreviations as in Table 1</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Clinical outcomes</title><p id="Par45">The FAS population contains 1204 patients, 1 patient was excluded due to protocol violation for having enrolled in another RCT, and 1-year follow-up was completed in 1196 patients (99.3%). As shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, the cumulative incidence of TLF at 1&#x000a0;year was 1.67%, with a 95% upper CI of 2.57%, significantly lower than the preset PG of 6.6% (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and the chosen expected rate (4.4%). Hence, the prespecified OPC goal for CFDA was achieved. The rate of single TLF components was 0.42% for cardiac death, 0.92% for TV-MI, and 0.42% for ID-TLR. The cumulative rate of POCE in 1204 patients was 3.34%, with all-cause death in 0.42%, any MI in 1.00%, and any revascularization in 2.01% of patients (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Periprocedural MI occurred in 0.75% of the FAS patients. There was no patient who experienced definite or probable DT within 12&#x000a0;months.<fig id="Fig1"><label>Fig. 1</label><caption><p>The cumulative incidence of TLF at 1-year follow-up. TLF, target lesion failure</p></caption><graphic xlink:href="12916_2025_4254_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>Clinical outcomes during 1-year follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">1&#x000a0;month</th><th align="left">6&#x000a0;months</th><th align="left">12&#x000a0;months</th></tr></thead><tbody><tr><td align="left">Target lesion failure</td><td align="left">12 (1.00)</td><td align="left">15 (1.25)</td><td align="left">20 (1.67)</td></tr><tr><td align="left">Patient-oriented composite endpoint</td><td align="left">12 (1.00)</td><td align="left">19 (1.58)</td><td align="left">40 (3.34)</td></tr><tr><td align="left">All-cause death</td><td align="left">1 (0.08)</td><td align="left">3 (0.25)</td><td align="left">5 (0.42)</td></tr><tr><td align="left">&#x02003;Cardiac death</td><td align="left">1 (0.08)</td><td align="left">3 (0.25)</td><td align="left">5 (0.42)</td></tr><tr><td align="left">Any MI</td><td align="left">10 (0.83)</td><td align="left">11 (0.92)</td><td align="left">12 (1.00)</td></tr><tr><td align="left">&#x02003;Target-vessel MI</td><td align="left">10 (0.83)</td><td align="left">11 (0.92)</td><td align="left">11 (0.92)</td></tr><tr><td align="left">&#x02003;Periprocedural MI</td><td align="left">9 (0.75)</td><td align="left">9 (0.75)</td><td align="left">9 (0.75)</td></tr><tr><td align="left">&#x02003;Spontaneous MI</td><td align="left">1 (0.08)</td><td align="left">2 (0.17)</td><td align="left">3 (0.25)</td></tr><tr><td align="left">Any revascularization</td><td align="left">1 (0.08)</td><td align="left">6 (0.50)</td><td align="left">24 (2.01)</td></tr><tr><td align="left">&#x02003;Ischemia-driven TVR</td><td align="left">1 (0.08)</td><td align="left">3 (0.25)</td><td align="left">8 (0.67)</td></tr><tr><td align="left">&#x02003;Ischemia-driven TLR</td><td align="left">1 (0.08)</td><td align="left">2 (0.17)</td><td align="left">5 (0.42)</td></tr><tr><td align="left">Definite/probable device thrombosis</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr></tbody></table><table-wrap-foot><p>Values are <italic>n</italic> (%). Results are estimated with the Kaplan&#x02013;Meier method, so values may not calculate mathematically</p><p>Target lesion failure was defined as a composite endpoint containing cardiac death, target vessel MI, or ischemia-driven TLR; patient-oriented composite endpoint was a composite of all-cause death, any MI, or any revascularization</p><p><italic>Abbreviations</italic>&#x000a0;<italic>MI</italic> myocardial infarction, <italic>TLR</italic> target lesion revascularization, <italic>TVR</italic>&#x000a0;target vessel revascularization</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>The cumulative incidence of <bold>A</bold> POCE, <bold>B</bold> death, <bold>C</bold> myocardial infarction, and <bold>D</bold> revascularization at 1-year follow-up. POCE, patient-oriented composite endpoint</p></caption><graphic xlink:href="12916_2025_4254_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec12"><title>Sub-analysis</title><p id="Par46">In the terms of the primary endpoint, TLF, no differences were observed across pre-specified subgroups of interest according to age, gender, smoking status, and presence or absence of cardiovascular comorbidities (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Subgroup analyses for the primary endpoint of 1-year TLF. TLF, target lesion failure; HR, hazard ratio; PCI, percutaneous coronary intervention; MI, myocardial infarction</p></caption><graphic xlink:href="12916_2025_4254_Fig3_HTML" id="MO3"/></fig></p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par47">The study pooled 1205 patients from the FUTURE-II RCT and FUTURE-III registry, evaluating the clinical outcomes of the Firesorb BRS in treating patients with native coronary lesions. Our main findings indicated that in patients who received the Firesorb BRS, the cumulative incidence of TLF at 1&#x000a0;year was 1.67%, significantly lower than the objective performance criterion goal of 6.6%. Meanwhile, the secondary endpoints, including POCE, the single components of POCE, and DT, were generally low, with high rates of procedural and clinical success. Overall, the thinner strut Firesorb BRS demonstrated favorable safety and efficacy in treating non-complex coronary lesions and achieved the preset OPC goal for TLF.</p><p id="Par48">Metallic stents currently pose an enduring risk of TLF [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], and BRS was thus developed to improve long-term outcomes with contemporary metallic DES. Several large RCTs have demonstrated that BRS was non-inferior to DES in terms of TLF rates at 1&#x000a0;year [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. However, evidence from a meta-analysis of RCT revealed a higher events rate of the bioresorbable scaffold compared to the metallic stent, driven by events that occurred within the first 3&#x000a0;years. The differences in TLF between BRS and CoCr-EES were similar during the 3- to 5-year follow-up period, when the poly-L-lactic acid had been fully absorbed [<xref ref-type="bibr" rid="CR8">8</xref>]. In the FUTURE-II RCT, we performed a head-to-head comparison between Firesorb BRS and CoCr-EES, demonstrating non-inferior angiographic in-segment late loss and comparable clinical outcomes at 1&#x000a0;year, although not powered for hard endpoints [<xref ref-type="bibr" rid="CR15">15</xref>]. In the present multicenter single-armed study, the 1-year TLF rate was 1.9%, with a markedly lower 95% upper CI of 2.9% compared to the OPC prespecified estimate of 6.6%, also appearing lower than those of other BRS, indicating the potential improved efficacy of the novel Firesorb BRS. Similar to our results, the Neovas BRS (Lepu Medical, Beijing, China) showed relatively low rates of both TLF and POCE [<xref ref-type="bibr" rid="CR25">25</xref>]. While definitive conclusions are precluded due to potential discrepancies in enrolled populations and procedures, the notably low rates of TLF and POCE presented in this pooled analysis strongly bolster the efficacy profile of the Firesorb BRS.</p><p id="Par49">Permanent vascular implant impairs arterial physiology, and the occurrence of very late DT remains a major concern [<xref ref-type="bibr" rid="CR26">26</xref>], while the occurrence of very late DT is decreased in the second-generation DES compared to that of the first-generation DES [<xref ref-type="bibr" rid="CR27">27</xref>]. This adverse complication primarily stems from the presence of permanent metallic implants, the chronic degeneration provoked by an inflammatory reaction to the coating polymer, and/or the negative impacts of antiproliferative drugs on endothelial regeneration [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Unlike the newer generation DES, BRS tend to exhibit a higher rate of DT within and beyond the first year of implantation. The final report of the ABSORB series studies, which pooled individual patient data from five RCTs involving 5988 patients, revealed higher DT rates through the 3-year follow-up period but showed comparable results between 3 and 5&#x000a0;years [<xref ref-type="bibr" rid="CR9">9</xref>]. However, consistent with the results from FUTURE-I and FUTURE-II studies [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], we reported that no patients developed DT during the 1-year follow-up, further confirming the safety profile of the Firesorb BRS.</p><p id="Par50">Currently, most BRSs are designed with thicker and wider struts compared to the newer generation DES, resulting in increased strut protrusion, turbulence flow, and platelet activation. The Firesorb BRS is manufactured with thinner struts (100 to 125&#x000a0;&#x003bc;m). In the FUTURE-II trial [<xref ref-type="bibr" rid="CR15">15</xref>], this device exhibited nearly identical angiographic in-segment late loss and tissue strut coverage as the CoCr-EES, with good expansion properties and low recoil forces as assessed by optical coherence tomography. Furthermore, the new everolimus-coated resorbable scaffold (Esprit-BTK, Abbott Vascular), with a 99- to 120-&#x003bc;m strut thickness, has shown superiority to angioplasty in patients with chronic limb-threatening ischemia due to infrapopliteal artery disease [<xref ref-type="bibr" rid="CR13">13</xref>]. A novel bioresorbable nitrided iron scaffold with 70-mm strut thickness has shown comparable 1-year efficacy and safety as CoCr-EES in porcine coronary arteries [<xref ref-type="bibr" rid="CR12">12</xref>]. Therefore, BRS developed with thinner struts may better improve fluid dynamics and facilitate accelerated and comprehensive endothelization. In addition, the following factors may also underlie this finding: (1) Strict entry criteria excluded high-risk patients with complex lesions, which could have potentially increased adverse events. (2) Adherence to the PSP principles. Specifically, precise vessel sizing was performed to avoid stenting very small vessels, and pre-dilation was conducted in 99.9% of all lesions. Post-dilation was performed in 95.3% of all lesions, with a mean pressure of 16.8&#x000a0;atm. This protocol resulted in optimal sizing in 67.6% of cases and achieved optimal post-dilation in 62.5% of lesions, demonstrating superior procedural outcomes compared to the Absorb BRS trials, which reported 50.2% optimal sizing and 12.7% optimal expansion rates [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. (3) High rate of DAPT prescription following BRS implantation. At the 1-year follow-up, 92.6% of patients remained on DAPT. Findings from the ABSORB and AIDA trials indicated a significantly lower risk of device thrombosis in patients maintained on DAPT compared to those off DAPT [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], we enforced more rigorous DAPT management for enrolled patients and recommended extending DAPT to 3&#x000a0;years to mitigate the risk of device thrombosis.</p><sec id="Sec14"><title>Study limitations</title><p id="Par51">Several limitations of our study should be noted. First, the FUTURE-III study had the usual limitations of a single-arm investigation with historical controls. RCTs represent the gold standard of scientific rigor utilized by FDA for assessing new devices and therapeutics, yet their utility in addressing individual clinical queries is often hindered by limited statistical power due to small sample sizes and economic and ethical issues of implementation [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. Hence, we used the OPC method to premarket evaluate the thinner strut Firesorb BRS. The unified outcome definitions, strict data management, and high follow-up rates may help mitigate bias and reconfirm the validity of this pooled analysis and the credibility of the conclusions. Second, enrollment in our study was confined to patients with relatively stable symptoms and uncomplicated coronary lesions. Although our findings met the prespecified PG, the observed event rates were lower than initially anticipated. This lower-than-expected event rate should be considered when interpreting the study results, as it might limit the generalizability to all-comer populations. However, in the INFINITY-SWEDEHEART trial, the TLF rate of contemporary DES at 1&#x000a0;year in the general population (including different types of acute coronary syndrome, complex lesions, long lesions, and small vessels) was 2.8% [<xref ref-type="bibr" rid="CR33">33</xref>]. These improvements can be attributed to the evolution and refinement of interventional devices as well as the optimization of medical treatment strategies. Third, the use of intravascular imaging techniques such as optical coherence tomography and intravascular ultrasound may enhance the optimization of vessel preparation, stent sizing, and post-dilatation processes for BRS. A recent Japanese study with a relatively small sample size, which used intracoronary imaging-guided BRS implantation, reported zero cases of ABSORB GT1 scaffold thrombosis over a 5-year follow-up [<xref ref-type="bibr" rid="CR34">34</xref>]. In our FUTURE III study, intravascular imaging was used in 15.3% of cases, yet the TLF rate was not significantly lower in this subgroup. It should be noted that the study protocol did not prespecify the use and data collection of intravascular imaging. Another RCT demonstrated no significant reduction in nonoptimal BRS deployment with OCT versus angiography guidance, with no long-term clinical data reported [<xref ref-type="bibr" rid="CR35">35</xref>]. Finally, although the clinical outcomes were promising, the current study only had 1&#x000a0;year of follow-up, which is insufficient to determine whether there are meaningful late clinical outcomes. Further follow-up investigation concerning the clinical endpoints is ongoing.</p></sec></sec><sec id="Sec15"><title>Conclusions</title><p id="Par52">In conclusion, this pooled, patient-level analysis indicates that the thinner strut Firesorb BRS achieves the OPC goal with regard to TLF at 1&#x000a0;year and exhibits promising efficacy and safety profiles in patients with de novo non-complex lesions.</p></sec><sec id="Sec16" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4254_MOESM1_ESM.docx"><caption><p>Additional file 1: Table S1. Summary of the FUTURE-III Study.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BRS</term><def><p id="Par22">Bioresorbable scaffolds</p></def></def-item><def-item><term>DAPT</term><def><p id="Par23">Dual antiplatelet therapy</p></def></def-item><def-item><term>DES</term><def><p id="Par24">Drug-eluting stent</p></def></def-item><def-item><term>DS</term><def><p id="Par25">Percent diameter stenosis</p></def></def-item><def-item><term>DT</term><def><p id="Par26">Device thrombosis</p></def></def-item><def-item><term>MI</term><def><p id="Par27">Myocardial infarction</p></def></def-item><def-item><term>MLD</term><def><p id="Par28">Minimum lumen diameter</p></def></def-item><def-item><term>PCI</term><def><p id="Par29">Percutaneous coronary intervention</p></def></def-item><def-item><term>PSP</term><def><p id="Par30">Pre-dilation, stent sizing and post-dilation</p></def></def-item><def-item><term>POCE</term><def><p id="Par31">Patient-oriented composite endpoint</p></def></def-item><def-item><term>QCA</term><def><p id="Par32">Quantitative coronary angiography</p></def></def-item><def-item><term>RCT</term><def><p id="Par33">Randomized controlled trial</p></def></def-item><def-item><term>RVD</term><def><p id="Par34">Reference vessel diameter</p></def></def-item><def-item><term>TLF</term><def><p id="Par35">Target lesion failure</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>A list of authors and their affiliations appears at the end of the paper.</p></fn></fn-group><ack><title>Acknowledgements
</title><p>We thank all the members who have contributed to this work.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>J.W., R.G. and J.J. designed the study and drafted the article. C.L., D.C., L.S., Z.C., P.L., L.G., Y.C., H.L., S.J., S.H., W.L. conducted subject enrollment and data acquisition, D.C. and J.J. performed data analysis and interpretation. J.W., R.G. and J.J. revised the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The study was funded by the National Science and Technology Major Project of the Ministry of Science and Technology of China (No. 2023ZD0504100), Transvascular Implantation Devices Research Institute (KY012024002), and the National Natural Science Foundation of China (No. 82170332).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The FUTURE III trial is planned to continue follow-up for 5&#x000a0;years. Patient-level data collected for this study will not be made publicly available. Any reasonable inquiries should be sent to the corresponding author.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par53">Our study was conducted in accordance with the Helsinki Declaration and was approved by the ethical review board of all participated centers (approval number: I2019001617 for The Second Affiliated Hospital, Zhejiang University School of Medicine, 2016-772 for Fu Wai Hospital, 2019-020 for Chinese PLA General Hospital, 2019-QX-011 for General Hospital of Ningxia Medical University, TZS-2021-002-01 for The First People&#x02019;s Hospital of Yulin, XZXY-LQ-20200109-005 for Xuzhou Central Hospital, 2020-002-01 for Inner Mongolia Autonomous Region People&#x02019;s Hospital, 2020-01-C for Affiliated Hospital of Jining Medical University, 2020-05-02 for Daqing Oilfield General Hospital, and 2020007 for Northern Jiangsu People&#x02019;s Hospital).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par54">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par55">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References
</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Lawton</surname><given-names>JS</given-names></name><name><surname>Tamis-Holland</surname><given-names>JE</given-names></name><name><surname>Bangalore</surname><given-names>S</given-names></name><name><surname>Bates</surname><given-names>ER</given-names></name><name><surname>Beckie</surname><given-names>TM</given-names></name><name><surname>Bischoff</surname><given-names>JM</given-names></name><etal/></person-group><article-title>2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</article-title><source>J Am Coll Cardiol</source><year>2022</year><volume>79</volume><issue>2</issue><fpage>e21</fpage><lpage>e129</lpage><?supplied-pmid 34895950?><pub-id pub-id-type="pmid">34895950</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(2):e21&#x02013;129.<pub-id pub-id-type="pmid">34895950</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Croce</surname><given-names>K</given-names></name><name><surname>Morooka</surname><given-names>T</given-names></name><name><surname>Sakuma</surname><given-names>M</given-names></name><name><surname>Node</surname><given-names>K</given-names></name><name><surname>Simon</surname><given-names>DI</given-names></name></person-group><article-title>Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis</article-title><source>JACC Cardiovasc Interv</source><year>2011</year><volume>4</volume><issue>10</issue><fpage>1057</fpage><lpage>1066</lpage><?supplied-pmid 22017929?><pub-id pub-id-type="pmid">22017929</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv. 2011;4(10):1057&#x02013;66.<pub-id pub-id-type="pmid">22017929</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Otsuka</surname><given-names>F</given-names></name><name><surname>Byrne</surname><given-names>RA</given-names></name><name><surname>Yahagi</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Ladich</surname><given-names>E</given-names></name><name><surname>Fowler</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment</article-title><source>Eur Heart J</source><year>2015</year><volume>36</volume><issue>32</issue><fpage>2147</fpage><lpage>2159</lpage><?supplied-pmid 25994755?><pub-id pub-id-type="pmid">25994755</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36(32):2147&#x02013;59.<pub-id pub-id-type="pmid">25994755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Otsuka</surname><given-names>F</given-names></name><name><surname>Pacheco</surname><given-names>E</given-names></name><name><surname>Perkins</surname><given-names>LE</given-names></name><name><surname>Lane</surname><given-names>JP</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Kamberi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model</article-title><source>Circ Cardiovasc Interv</source><year>2014</year><volume>7</volume><issue>3</issue><fpage>330</fpage><lpage>342</lpage><?supplied-pmid 24895447?><pub-id pub-id-type="pmid">24895447</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Otsuka F, Pacheco E, Perkins LE, Lane JP, Wang Q, Kamberi M, et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014;7(3):330&#x02013;42.<pub-id pub-id-type="pmid">24895447</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Serruys</surname><given-names>PW</given-names></name><name><surname>Chevalier</surname><given-names>B</given-names></name><name><surname>Dudek</surname><given-names>D</given-names></name><name><surname>Cequier</surname><given-names>A</given-names></name><name><surname>Carri&#x000e9;</surname><given-names>D</given-names></name><name><surname>Iniguez</surname><given-names>A</given-names></name><etal/></person-group><article-title>A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial</article-title><source>Lancet</source><year>2015</year><volume>385</volume><issue>9962</issue><fpage>43</fpage><lpage>54</lpage><?supplied-pmid 25230593?><pub-id pub-id-type="pmid">25230593</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Serruys PW, Chevalier B, Dudek D, Cequier A, Carri&#x000e9; D, Iniguez A, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385(9962):43&#x02013;54.<pub-id pub-id-type="pmid">25230593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>SG</given-names></name><name><surname>Kereiakes</surname><given-names>DJ</given-names></name><name><surname>Metzger</surname><given-names>DC</given-names></name><name><surname>Caputo</surname><given-names>RP</given-names></name><name><surname>Rizik</surname><given-names>DG</given-names></name><name><surname>Teirstein</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><issue>20</issue><fpage>1905</fpage><lpage>1915</lpage><?supplied-pmid 26457558?><pub-id pub-id-type="pmid">26457558</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015;373(20):1905&#x02013;15.<pub-id pub-id-type="pmid">26457558</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Serruys</surname><given-names>PW</given-names></name><name><surname>Ormiston</surname><given-names>J</given-names></name><name><surname>van Geuns</surname><given-names>RJ</given-names></name><name><surname>de Bruyne</surname><given-names>B</given-names></name><name><surname>Dudek</surname><given-names>D</given-names></name><name><surname>Christiansen</surname><given-names>E</given-names></name><etal/></person-group><article-title>A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up</article-title><source>J Am Coll Cardiol</source><year>2016</year><volume>67</volume><issue>7</issue><fpage>766</fpage><lpage>776</lpage><?supplied-pmid 26892411?><pub-id pub-id-type="pmid">26892411</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Serruys PW, Ormiston J, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, et al. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up. J Am Coll Cardiol. 2016;67(7):766&#x02013;76.<pub-id pub-id-type="pmid">26892411</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Power</surname><given-names>DA</given-names></name><name><surname>Camaj</surname><given-names>A</given-names></name><name><surname>Kereiakes</surname><given-names>DJ</given-names></name><name><surname>Ellis</surname><given-names>SG</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><etal/></person-group><article-title>Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold: Final Report From the ABSORB Clinical Trial Program</article-title><source>JACC Cardiovasc Interv</source><year>2025</year><volume>18</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><?supplied-pmid 39814482?><pub-id pub-id-type="pmid">39814482</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Power DA, Camaj A, Kereiakes DJ, Ellis SG, Gao R, Kimura T, et al. Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold: Final Report From the ABSORB Clinical Trial Program. JACC Cardiovasc Interv. 2025;18(1):1&#x02013;11.<pub-id pub-id-type="pmid">39814482</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Kereiakes</surname><given-names>DJ</given-names></name><name><surname>Ellis</surname><given-names>SG</given-names></name><name><surname>Onuma</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study</article-title><source>JAMA Cardiol</source><year>2019</year><volume>4</volume><issue>12</issue><fpage>1261</fpage><lpage>1269</lpage><?supplied-pmid 31561250?><pub-id pub-id-type="pmid">31561250</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Stone GW, Kimura T, Gao R, Kereiakes DJ, Ellis SG, Onuma Y, et al. Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study. JAMA Cardiol. 2019;4(12):1261&#x02013;9.<pub-id pub-id-type="pmid">31561250</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaji</surname><given-names>K</given-names></name><name><surname>Ueki</surname><given-names>Y</given-names></name><name><surname>Souteyrand</surname><given-names>G</given-names></name><name><surname>Daemen</surname><given-names>J</given-names></name><name><surname>Wiebe</surname><given-names>J</given-names></name><name><surname>Nef</surname><given-names>H</given-names></name><etal/></person-group><article-title>Mechanisms of Very Late Bioresorbable Scaffold Thrombosis: The INVEST Registry</article-title><source>J Am Coll Cardiol</source><year>2017</year><volume>70</volume><issue>19</issue><fpage>2330</fpage><lpage>2344</lpage><?supplied-pmid 29096803?><pub-id pub-id-type="pmid">29096803</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Yamaji K, Ueki Y, Souteyrand G, Daemen J, Wiebe J, Nef H, et al. Mechanisms of Very Late Bioresorbable Scaffold Thrombosis: The INVEST Registry. J Am Coll Cardiol. 2017;70(19):2330&#x02013;44.<pub-id pub-id-type="pmid">29096803</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Tenekecioglu</surname><given-names>E</given-names></name><name><surname>Torii</surname><given-names>R</given-names></name><name><surname>Katagiri</surname><given-names>Y</given-names></name><name><surname>Asano</surname><given-names>T</given-names></name><name><surname>Modolo</surname><given-names>R</given-names></name><name><surname>Miyazaki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Early strut protrusion and late neointima thickness in the Absorb bioresorbable scaffold: a serial wall shear stress analysis up to five years</article-title><source>EuroIntervention</source><year>2019</year><volume>15</volume><issue>4</issue><fpage>e370</fpage><lpage>e379</lpage><?supplied-pmid 29969424?><pub-id pub-id-type="pmid">29969424</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Tenekecioglu E, Torii R, Katagiri Y, Asano T, Modolo R, Miyazaki Y, et al. Early strut protrusion and late neointima thickness in the Absorb bioresorbable scaffold: a serial wall shear stress analysis up to five years. EuroIntervention. 2019;15(4):e370&#x02013;9.<pub-id pub-id-type="pmid">29969424</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>JF</given-names></name><name><surname>Xi</surname><given-names>ZW</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>JN</given-names></name><name><surname>Qiu</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>XY</given-names></name><etal/></person-group><article-title>Long-term safety and absorption assessment of a novel bioresorbable nitrided iron scaffold in porcine coronary artery</article-title><source>Bioact Mater</source><year>2022</year><volume>17</volume><fpage>496</fpage><lpage>505</lpage><?supplied-pmid 35415293?><pub-id pub-id-type="pmid">35415293</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Zheng JF, Xi ZW, Li Y, Li JN, Qiu H, Hu XY, et al. Long-term safety and absorption assessment of a novel bioresorbable nitrided iron scaffold in porcine coronary artery. Bioact Mater. 2022;17:496&#x02013;505.<pub-id pub-id-type="pmid">35415293</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Varcoe</surname><given-names>RL</given-names></name><name><surname>DeRubertis</surname><given-names>BG</given-names></name><name><surname>Kolluri</surname><given-names>R</given-names></name><name><surname>Krishnan</surname><given-names>P</given-names></name><name><surname>Metzger</surname><given-names>DC</given-names></name><name><surname>Bonaca</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease</article-title><source>N Engl J Med</source><year>2024</year><volume>390</volume><issue>1</issue><fpage>9</fpage><lpage>19</lpage><?supplied-pmid 37888915?><pub-id pub-id-type="pmid">37888915</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Varcoe RL, DeRubertis BG, Kolluri R, Krishnan P, Metzger DC, Bonaca MP, et al. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Engl J Med. 2024;390(1):9&#x02013;19.<pub-id pub-id-type="pmid">37888915</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Guan</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><etal/></person-group><article-title>First-in-man study of a thinner-strut sirolimus-eluting bioresorbable scaffold (FUTURE-I): Three-year clinical and imaging outcomes</article-title><source>Catheter Cardiovasc Interv</source><year>2020</year><volume>95</volume><issue>Suppl 1</issue><fpage>648</fpage><lpage>657</lpage><?supplied-pmid 31909884?><pub-id pub-id-type="pmid">31909884</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Song L, Sun Z, Guan C, Yan H, Yu M, Cui J, et al. First-in-man study of a thinner-strut sirolimus-eluting bioresorbable scaffold (FUTURE-I): Three-year clinical and imaging outcomes. Catheter Cardiovasc Interv. 2020;95(Suppl 1):648&#x02013;57.<pub-id pub-id-type="pmid">31909884</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Thinner Strut Sirolimus-Eluting BRS Versus EES in Patients With Coronary Artery Disease: FUTURE-II Trial</article-title><source>JACC Cardiovasc Interv</source><year>2021</year><volume>14</volume><issue>13</issue><fpage>1450</fpage><lpage>1462</lpage><?supplied-pmid 34238555?><pub-id pub-id-type="pmid">34238555</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Song L, Xu B, Chen Y, Zhou Y, Jia S, Zhong Z, et al. Thinner Strut Sirolimus-Eluting BRS Versus EES in Patients With Coronary Artery Disease: FUTURE-II Trial. JACC Cardiovasc Interv. 2021;14(13):1450&#x02013;62.<pub-id pub-id-type="pmid">34238555</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Abizaid</surname><given-names>A</given-names></name><name><surname>Onuma</surname><given-names>Y</given-names></name><name><surname>Seth</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Ormiston</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis From the ABSORB Trials</article-title><source>J Am Coll Cardiol</source><year>2017</year><volume>70</volume><issue>23</issue><fpage>2863</fpage><lpage>2874</lpage><?supplied-pmid 29100704?><pub-id pub-id-type="pmid">29100704</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Stone GW, Abizaid A, Onuma Y, Seth A, Gao R, Ormiston J, et al. Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis From the ABSORB Trials. J Am Coll Cardiol. 2017;70(23):2863&#x02013;74.<pub-id pub-id-type="pmid">29100704</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega-Paz</surname><given-names>L</given-names></name><name><surname>Capodanno</surname><given-names>D</given-names></name><name><surname>Gori</surname><given-names>T</given-names></name><name><surname>Nef</surname><given-names>H</given-names></name><name><surname>Latib</surname><given-names>A</given-names></name><name><surname>Caramanno</surname><given-names>G</given-names></name><etal/></person-group><article-title>Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score</article-title><source>EuroIntervention</source><year>2017</year><volume>12</volume><issue>17</issue><fpage>2110</fpage><lpage>2117</lpage><?supplied-pmid 28246060?><pub-id pub-id-type="pmid">28246060</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ortega-Paz L, Capodanno D, Gori T, Nef H, Latib A, Caramanno G, et al. Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. EuroIntervention. 2017;12(17):2110&#x02013;7.<pub-id pub-id-type="pmid">28246060</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Gori</surname><given-names>T</given-names></name><name><surname>Weissner</surname><given-names>M</given-names></name><name><surname>G&#x000f6;nner</surname><given-names>S</given-names></name><name><surname>Wendling</surname><given-names>F</given-names></name><name><surname>Ullrich</surname><given-names>H</given-names></name><name><surname>Ellis</surname><given-names>S</given-names></name><etal/></person-group><article-title>Characteristics, Predictors, and Mechanisms of Thrombosis in Coronary Bioresorbable Scaffolds: Differences Between Early and Late Events</article-title><source>JACC Cardiovasc Interv</source><year>2017</year><volume>10</volume><issue>23</issue><fpage>2363</fpage><lpage>2371</lpage><?supplied-pmid 29216999?><pub-id pub-id-type="pmid">29216999</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Gori T, Weissner M, G&#x000f6;nner S, Wendling F, Ullrich H, Ellis S, et al. Characteristics, Predictors, and Mechanisms of Thrombosis in Coronary Bioresorbable Scaffolds: Differences Between Early and Late Events. JACC Cardiovasc Interv. 2017;10(23):2363&#x02013;71.<pub-id pub-id-type="pmid">29216999</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name><name><surname>Chaitman</surname><given-names>BR</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>Morrow</surname><given-names>DA</given-names></name><name><surname>White</surname><given-names>HD</given-names></name></person-group><article-title>Fourth Universal Definition of Myocardial Infarction (2018)</article-title><source>J Am Coll Cardiol</source><year>2018</year><volume>72</volume><issue>18</issue><fpage>2231</fpage><lpage>2264</lpage><?supplied-pmid 30153967?><pub-id pub-id-type="pmid">30153967</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231&#x02013;64.<pub-id pub-id-type="pmid">30153967</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Kereiakes</surname><given-names>DJ</given-names></name><name><surname>Ellis</surname><given-names>SG</given-names></name><name><surname>Onuma</surname><given-names>Y</given-names></name><etal/></person-group><article-title>1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis</article-title><source>Lancet</source><year>2016</year><volume>387</volume><issue>10025</issue><fpage>1277</fpage><lpage>1289</lpage><?supplied-pmid 26825231?><pub-id pub-id-type="pmid">26825231</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Stone GW, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387(10025):1277&#x02013;89.<pub-id pub-id-type="pmid">26825231</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><etal/></person-group><article-title>Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: 12-month results from the TARGET II trial</article-title><source>Chin Med J (Engl)</source><year>2014</year><volume>127</volume><issue>6</issue><fpage>1027</fpage><lpage>1032</lpage><?supplied-pmid 24622429?><pub-id pub-id-type="pmid">24622429</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Xu B, Zhao Y, Yang Y, Zhang R, Li H, Ma C, et al. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: 12-month results from the TARGET II trial. Chin Med J (Engl). 2014;127(6):1027&#x02013;32.<pub-id pub-id-type="pmid">24622429</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Taglieri</surname><given-names>N</given-names></name><name><surname>Bruno</surname><given-names>AG</given-names></name><name><surname>Ghetti</surname><given-names>G</given-names></name><name><surname>Marrozzini</surname><given-names>C</given-names></name><name><surname>Saia</surname><given-names>F</given-names></name><name><surname>Gali&#x000e9;</surname><given-names>N</given-names></name><name><surname>Palmerini</surname><given-names>T</given-names></name></person-group><article-title>Target Lesion Failure With Current Drug-Eluting Stents: Evidence From a Comprehensive Network Meta-Analysis</article-title><source>JACC Cardiovasc Interv</source><year>2020</year><volume>13</volume><issue>24</issue><fpage>2868</fpage><lpage>2878</lpage><?supplied-pmid 33357524?><pub-id pub-id-type="pmid">33357524</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Taglieri N, Bruno AG, Ghetti G, Marrozzini C, Saia F, Gali&#x000e9; N, Palmerini T. Target Lesion Failure With Current Drug-Eluting Stents: Evidence From a Comprehensive Network Meta-Analysis. JACC Cardiovasc Interv. 2020;13(24):2868&#x02013;78.<pub-id pub-id-type="pmid">33357524</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>KH</given-names></name><name><surname>Song</surname><given-names>YB</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Park</surname><given-names>TK</given-names></name><name><surname>Yang</surname><given-names>JH</given-names></name><name><surname>Hahn</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Differential Long-Term Effects of First- and Second-Generation DES in Patients With Bifurcation Lesions Undergoing PCI</article-title><source>JACC Asia</source><year>2021</year><volume>1</volume><issue>1</issue><fpage>68</fpage><lpage>79</lpage><?supplied-pmid 36338362?><pub-id pub-id-type="pmid">36338362</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Choi KH, Song YB, Lee JM, Park TK, Yang JH, Hahn JY, et al. Differential Long-Term Effects of First- and Second-Generation DES in Patients With Bifurcation Lesions Undergoing PCI. JACC Asia. 2021;1(1):68&#x02013;79.<pub-id pub-id-type="pmid">36338362</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Ellis</surname><given-names>SG</given-names></name><name><surname>Gori</surname><given-names>T</given-names></name><name><surname>Metzger</surname><given-names>DC</given-names></name><name><surname>Stein</surname><given-names>B</given-names></name><name><surname>Erickson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial</article-title><source>Lancet</source><year>2018</year><volume>392</volume><issue>10157</issue><fpage>1530</fpage><lpage>1540</lpage><?supplied-pmid 30266412?><pub-id pub-id-type="pmid">30266412</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet. 2018;392(10157):1530&#x02013;40.<pub-id pub-id-type="pmid">30266412</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials</article-title><source>Catheter Cardiovasc Interv</source><year>2019</year><volume>93</volume><issue>S1</issue><fpage>832</fpage><lpage>838</lpage><?supplied-pmid 30888736?><pub-id pub-id-type="pmid">30888736</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Xu K, Fu G, Xu B, Zhou Y, Su X, Liu H, et al. Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials. Catheter Cardiovasc Interv. 2019;93(S1):832&#x02013;8.<pub-id pub-id-type="pmid">30888736</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Taniwaki</surname><given-names>M</given-names></name><name><surname>Radu</surname><given-names>MD</given-names></name><name><surname>Zaugg</surname><given-names>S</given-names></name><name><surname>Amabile</surname><given-names>N</given-names></name><name><surname>Garcia-Garcia</surname><given-names>HM</given-names></name><name><surname>Yamaji</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography</article-title><source>Circulation</source><year>2016</year><volume>133</volume><issue>7</issue><fpage>650</fpage><lpage>660</lpage><?supplied-pmid 26762519?><pub-id pub-id-type="pmid">26762519</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Taniwaki M, Radu MD, Zaugg S, Amabile N, Garcia-Garcia HM, Yamaji K, et al. Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography. Circulation. 2016;133(7):650&#x02013;60.<pub-id pub-id-type="pmid">26762519</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Palmerini</surname><given-names>T</given-names></name><name><surname>Biondi-Zoccai</surname><given-names>G</given-names></name><name><surname>Della Riva</surname><given-names>D</given-names></name><name><surname>Stettler</surname><given-names>C</given-names></name><name><surname>Sangiorgi</surname><given-names>D</given-names></name><name><surname>D'Ascenzo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis</article-title><source>Lancet</source><year>2012</year><volume>379</volume><issue>9824</issue><fpage>1393</fpage><lpage>1402</lpage><?supplied-pmid 22445239?><pub-id pub-id-type="pmid">22445239</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D&#x02019;Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379(9824):1393&#x02013;402.<pub-id pub-id-type="pmid">22445239</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Collet</surname><given-names>C</given-names></name><name><surname>Asano</surname><given-names>T</given-names></name><name><surname>Miyazaki</surname><given-names>Y</given-names></name><name><surname>Tenekecioglu</surname><given-names>E</given-names></name><name><surname>Katagiri</surname><given-names>Y</given-names></name><name><surname>Sotomi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><issue>33</issue><fpage>2559</fpage><lpage>2566</lpage><?supplied-pmid 28430908?><pub-id pub-id-type="pmid">28430908</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Collet C, Asano T, Miyazaki Y, Tenekecioglu E, Katagiri Y, Sotomi Y, et al. Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2017;38(33):2559&#x02013;66.<pub-id pub-id-type="pmid">28430908</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Kerkmeijer</surname><given-names>LSM</given-names></name><name><surname>Renkens</surname><given-names>MPL</given-names></name><name><surname>Tijssen</surname><given-names>RYG</given-names></name><name><surname>Hofma</surname><given-names>SH</given-names></name><name><surname>van der Schaaf</surname><given-names>RJ</given-names></name><name><surname>Arkenbout</surname><given-names>EK</given-names></name><etal/></person-group><article-title>Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial</article-title><source>EuroIntervention</source><year>2022</year><volume>17</volume><issue>16</issue><fpage>1340</fpage><lpage>1347</lpage><?supplied-pmid 34483094?><pub-id pub-id-type="pmid">34483094</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Kerkmeijer LSM, Renkens MPL, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout EK, et al. Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial. EuroIntervention. 2022;17(16):1340&#x02013;7.<pub-id pub-id-type="pmid">34483094</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>RB</given-names></name><name><surname>Woodcock</surname><given-names>J</given-names></name><name><surname>Norden</surname><given-names>J</given-names></name><name><surname>Grandinetti</surname><given-names>C</given-names></name><name><surname>Temple</surname><given-names>RJ</given-names></name></person-group><article-title>New FDA regulation to improve safety reporting in clinical trials</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>1</issue><fpage>3</fpage><lpage>5</lpage><?supplied-pmid 21651388?><pub-id pub-id-type="pmid">21651388</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Sherman RB, Woodcock J, Norden J, Grandinetti C, Temple RJ. New FDA regulation to improve safety reporting in clinical trials. N Engl J Med. 2011;365(1):3&#x02013;5.<pub-id pub-id-type="pmid">21651388</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Zabor</surname><given-names>EC</given-names></name><name><surname>Kaizer</surname><given-names>AM</given-names></name><name><surname>Hobbs</surname><given-names>BP</given-names></name></person-group><article-title>Randomized Controlled Trials</article-title><source>Chest</source><year>2020</year><volume>158</volume><issue>1s</issue><fpage>S79</fpage><lpage>s87</lpage><?supplied-pmid 32658656?><pub-id pub-id-type="pmid">32658656</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Zabor EC, Kaizer AM, Hobbs BP. Randomized Controlled Trials. Chest. 2020;158(1s):S79-s87.<pub-id pub-id-type="pmid">32658656</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>CE</given-names></name><name><surname>Weijer</surname><given-names>C</given-names></name><name><surname>Brehaut</surname><given-names>JC</given-names></name><name><surname>Fergusson</surname><given-names>DA</given-names></name><name><surname>Grimshaw</surname><given-names>JM</given-names></name><name><surname>Horn</surname><given-names>AR</given-names></name><name><surname>Taljaard</surname><given-names>M</given-names></name></person-group><article-title>Ethical issues in pragmatic randomized controlled trials: a review of the recent literature identifies gaps in ethical argumentation</article-title><source>BMC Med Ethics</source><year>2018</year><volume>19</volume><issue>1</issue><fpage>14</fpage><?supplied-pmid 29482537?><pub-id pub-id-type="pmid">29482537</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Goldstein CE, Weijer C, Brehaut JC, Fergusson DA, Grimshaw JM, Horn AR, Taljaard M. Ethical issues in pragmatic randomized controlled trials: a review of the recent literature identifies gaps in ethical argumentation. BMC Med Ethics. 2018;19(1):14.<pub-id pub-id-type="pmid">29482537</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Erlinge</surname><given-names>D</given-names></name><name><surname>Andersson</surname><given-names>J</given-names></name><name><surname>Fr&#x000f6;bert</surname><given-names>O</given-names></name><name><surname>T&#x000f6;rnerud</surname><given-names>M</given-names></name><name><surname>Hamid</surname><given-names>M</given-names></name><name><surname>Kellerth</surname><given-names>T</given-names></name><etal/></person-group><article-title>Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial</article-title><source>Lancet</source><year>2024</year><volume>404</volume><issue>10464</issue><fpage>1750</fpage><lpage>1759</lpage><?supplied-pmid 39481425?><pub-id pub-id-type="pmid">39481425</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Erlinge D, Andersson J, Fr&#x000f6;bert O, T&#x000f6;rnerud M, Hamid M, Kellerth T, et al. Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial. Lancet. 2024;404(10464):1750&#x02013;9.<pub-id pub-id-type="pmid">39481425</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><name><surname>Furuya</surname><given-names>J</given-names></name><name><surname>Kawasaki</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><etal/></person-group><article-title>The Absorb GT1 Bioresorbable Vascular Scaffold System - 5-Year Post-Market Surveillance Study in Japan</article-title><source>Circ J</source><year>2024</year><volume>88</volume><issue>6</issue><fpage>863</fpage><lpage>872</lpage><?supplied-pmid 38479861?><pub-id pub-id-type="pmid">38479861</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Nakamura M, Suzuki N, Fujii K, Furuya J, Kawasaki T, Kimura T, et al. The Absorb GT1 Bioresorbable Vascular Scaffold System - 5-Year Post-Market Surveillance Study in Japan. Circ J. 2024;88(6):863&#x02013;72.<pub-id pub-id-type="pmid">38479861</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Kang</surname><given-names>DY</given-names></name><name><surname>Hong</surname><given-names>SJ</given-names></name><name><surname>Ahn</surname><given-names>JM</given-names></name><name><surname>Ahn</surname><given-names>CM</given-names></name><name><surname>Park</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Optical Coherence Tomography for Coronary Bioresorbable Vascular Scaffold Implantation: A Randomized Controlled Trial</article-title><source>Circ Cardiovasc Interv</source><year>2020</year><volume>13</volume><issue>1</issue><fpage>e008383</fpage><?supplied-pmid 32525410?><pub-id pub-id-type="pmid">32525410</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Lee SY, Kang DY, Hong SJ, Ahn JM, Ahn CM, Park DW, et al. Optical Coherence Tomography for Coronary Bioresorbable Vascular Scaffold Implantation: A Randomized Controlled Trial. Circ Cardiovasc Interv. 2020;13(1): e008383.<pub-id pub-id-type="pmid">32525410</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>